• Bacterial infections

Vibativ Generic Name & Formulations

General Description

Telavancin (as HCl) 750mg; per vial; lyophilized pwd for IV infusion after reconstitution and dilution; preservative-free.

Pharmacological Class


How Supplied

Single-use vials—10

Generic Availability


Vibativ Indications


Complicated skin and skin structure infections (cSSSI) due to susceptible gram (+) bacteria. Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) due to Staphylococcus aureus (reserve use when no alternatives).

Vibativ Dosage and Administration


≥18yrs: Give by IV infusion over 60mins. cSSSI: treat for 7–14 days. HABP/VABP: treat for 7–21 days. Normal renal function: 10mg/kg once every 24hrs. Renal impairment: CrCl 30–50mL/min: 7.5mg/kg every 24hrs; CrCl 10–<30mL/min: 10mg/kg every 48hrs; CrCl<10mL/min or dialysis: not recommended.


<18yrs: not established.

Vibativ Contraindications


Concomitant IV unfractionated heparin sodium.

Vibativ Boxed Warnings

Boxed Warning

Increased mortality in HABP/VABP patients with pre-existing moderate or severe renal impairment. Nephrotoxicity. Potential adverse developmental outcomes.

Vibativ Warnings/Precautions


Increased mortality in patients with pre-existing moderate/severe renal impairment who were treated for HABP/VABP. Baseline CrCl≤50mL/min. Risk of nephrotoxicity; monitor renal function. Embryo-fetal toxicity. Advise females of reproductive potential to use effective contraception during and for 2 days after last dose. Diabetes. CHF. Hypertension. Discontinue at first sign of rash or any other sign of hypersensitivity reaction. Known hypersensitivity to vancomycin. Congenital long QT syndrome, uncompensated heart failure, severe left ventricular hypertrophy: avoid. Pregnancy: exclude status prior to initiation. Nursing mothers.

Vibativ Pharmacokinetics

See Literature

Vibativ Interactions


Caution with other drugs that can cause QT prolongation. Increased risk of renal toxicity with NSAIDs, ACE inhibitors, loop diuretics. May interfere with coagulation tests (eg, PT/INR, aPPT, activated clotting time, coagulation-based factor Xa tests) and some urine protein tests.

Vibativ Adverse Reactions

Adverse Reactions

Dysgeusia, nausea, vomiting, foamy urine, diarrhea; nephrotoxicity, infusion reactions ("red man syndrome"), superinfection, QT prolongation, C.difficile-associated diarrhea.

Vibativ Clinical Trials

See Literature

Vibativ Note

Not Applicable

Vibativ Patient Counseling

See Literature